Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $43.6 Million - $76.5 Million
-524,000 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$110.08 - $142.92 $6.16 Million - $8 Million
56,000 Added 11.97%
524,000 $62.1 Million
Q4 2021

Feb 14, 2022

BUY
$99.73 - $148.48 $9.18 Million - $13.7 Million
92,000 Added 24.47%
468,000 $64.5 Million
Q3 2021

Nov 15, 2021

SELL
$98.85 - $138.91 $12.3 Million - $17.2 Million
-124,000 Reduced 24.8%
376,000 $52.2 Million
Q2 2021

Aug 16, 2021

SELL
$65.78 - $105.02 $32.9 Million - $52.5 Million
-500,000 Reduced 50.0%
500,000 $48.5 Million
Q1 2021

May 17, 2021

BUY
$64.07 - $91.75 $27.4 Million - $39.3 Million
428,000 Added 74.83%
1,000,000 $68.4 Million
Q4 2020

Feb 16, 2021

SELL
$65.07 - $98.24 $21.3 Million - $32.2 Million
-328,000 Reduced 36.44%
572,000 $49 Million
Q3 2020

Nov 16, 2020

BUY
$59.04 - $77.95 $23.6 Million - $31.2 Million
400,000 Added 80.0%
900,000 $58.5 Million
Q2 2020

Aug 14, 2020

SELL
$29.01 - $74.23 $16.1 Million - $41.3 Million
-556,000 Reduced 52.65%
500,000 $36.6 Million
Q1 2020

May 15, 2020

BUY
$27.51 - $57.29 $12.2 Million - $25.4 Million
444,000 Added 72.55%
1,056,000 $35.9 Million
Q4 2019

Feb 14, 2020

BUY
$40.86 - $57.65 $1.39 Million - $1.96 Million
34,000 Added 5.88%
612,000 $33.3 Million
Q3 2019

Nov 14, 2019

BUY
$37.38 - $49.47 $15.6 Million - $20.7 Million
418,000 Added 261.25%
578,000 $24.1 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $6.37 Million - $10.7 Million
160,000 New
160,000 $7.01 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.